BiotechTube

AK111 + AK111 + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Psoriasis

Conditions

Psoriasis, Skin Diseases

Trial Timeline

Mar 31, 2023 → Aug 19, 2024

NCT ID
NCT06066125

About AK111 + AK111 + Placebo

AK111 + AK111 + Placebo is a phase 3 stage product being developed by Akeso for Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT06066125. Target conditions include Psoriasis, Skin Diseases.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06066125Phase 3Completed

Competing Products

20 competing products in Psoriasis

See all competitors
ProductCompanyStageHype Score
Ixekizumab + PlaceboEli LillyPhase 2
52
VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + PlaceboVentyx BiosciencesPhase 2
47
LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo SubcutaneousEli LillyPhase 2
52
IxekizumabEli LillyPhase 3
77
80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + PlaceboEli LillyPhase 3
77
Placebo + BaricitinibEli LillyPhase 2
52
CT-P43 + StelaraCelltrionPhase 3
77
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
CT-P55 + EU-approved CosentyxCelltrionPhase 3
77
AMG 139AstraZenecaPhase 1
33
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
85
alefaceptAstellas PharmaPhase 2
52
Tacrolimus CreamAstellas PharmaPhase 3
77
alefaceptAstellas PharmaPhase 3
77
peficitinib + PlaceboAstellas PharmaPhase 2
52
AlefaceptAstellas PharmaPhase 3
77
Amevive exposureAstellas PharmaPre-clinical
23
alefacept + placeboAstellas PharmaPhase 3
77
alefaceptAstellas PharmaApproved
85
ASKP1240 + PlaceboAstellas PharmaPhase 2
52

Other Products from Akeso

AK104(SC) + AK104(IV) + Capecitabine + Oxaliplatin injectionPhase 3
76
AK104 + LenvatinibPhase 3
76
Cadonilimab (AK104) + Oxaliplatin + Capecitabine + 5- Fluorouracil + Calcium FolinatePhase 3
76
AK102 + AK102 + Placebo + PlaceboPhase 3
76
Penpulimab + placeboPhase 3
76